CHICAGO, Apr 18: Geminii, Inc., a company developing bioelectronic medicines, today announced that it will present new data at the AACR Annual Meeting 2026 in San Diego highlighting its non-small cell lung cancer (NSCLC) program. The poster, titled “Bioelectromagnetic reprogramming of tumor-immune metabolism to selectively destroy NSCLC,” will be presented on April 22, 2026.
The data to be presented show that Geminii’s bioelectronic therapy slowed tumor growth, extended survival, and enhanced the activity of chemoradiation in multiple preclinical NSCLC models without toxicity to healthy tissue. The studies also show increased markers consistent with tumor-cell damage and evidence of increased immune activation in the tumor microenvironment.
Geminii is developing a non-invasive bioelectronic therapy designed to work alongside existing cancer treatments. The company believes these findings support the potential of its platform to address cancer through a differentiated mechanism, expand the reach of its platform beyond metabolic disease into oncology, and potentially open a new avenue for home-based cancer treatment delivered during sleep.
“These findings are exciting not only because they highlight a differentiated approach in NSCLC, but also because they suggest our platform may extend beyond metabolic disease into oncology,” said Calvin Carter, PhD, CEO of Geminii. “We believe this work supports the broader potential of bioelectronic medicine and may help open a new avenue for at-home, sleep-compatible cancer therapy. These data support the advancement of our bioelectronic platform toward clinical development.”
